Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury

Part 1

Discovery's new paradigm

Part 2

Human-first neurology

Part 3

I&I's next targets

Part 4

Biomarkers wanted

Part 5

AI's long road

Back to School

Editor's letter

Part 6

Podcast

ARTICLE | Discovery & Translation

Eyes on the target: Drug discovery’s new paradigm

Back to School 2024: Can biotech write a more successful playbook for translating from target to product?

By C. Simone Fishburn, Editor in Chief, Selina Koch, Executive Editor and Lauren Martz, Executive Director of Biopharma Intelligence
September 3, 2024 10:22 PM UTC

Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.

If success in creating groundbreaking therapies boils down to one thing, it can be argued that it’s about picking the right target. From there cascade the modality, indication, patient population and other features that define the product, but none of it matters if the target is wrong. ...

Get Unlimited Access
To view this item, login or register for a free account.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Alto Neuroscience Inc.

Benevolentai S.A.

Bristol Myers Squibb Co.

Candel Therapeutics Inc.

Muna Therapeutics ApS

New York University School of Medicine

Novartis AG